NCT04007835 2019-07-05
Anlotinib Hydrochloride Combined With EGFR-Tyrosine Kinase Inhibitor (TKI) in Treating Advanced NSCLC Patients With Acquired Resistance to EGFR-TKI
Guangdong Association of Clinical Trials
Phase NA Unknown
Clinical Trials
3 trialsNCT02140333 2015-02-12
Erlotinib 100mg or 150mg in Treating EGFR Mutated NSCLC
The First Affiliated Hospital of Guangzhou Medical University
Phase 3 Unknown
NCT00283634 2011-02-17
A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer
Millennium Pharmaceuticals, Inc.
Phase 2 Terminated